Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 IMS is releasing updates ... to the web and provide greater accessibility and ... reporting metrics increase data warehouse’s utility; plus, the ... and access “on-the-go” makes data analysis even easier. ... feedback to assist in repository analytics and business ...
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... 27, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the year ended December 31, 2014. ... dollars and presented under International Financial Reporting Standards ... results did not provide the outcome management and ... remain at iCo Therapeutics", said Andrew Rae ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 Deadly ... Therapeutics, the newest resident of the University City ... Street in Philadelphia. , With a $4.5 million ... Health in hand, Phelix Therapeutics is focused ... developing nutritional supplements. The company is developing first-in-class protease ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2
... towards building a microscopic device that can construct nano ... the peer-reviewed publication, International Journal of Nanomanufacturing from Inderscience ... , In his 1986 book, The Engines of Creation, ... nanotechnology - to create an assembler, a microscopic device, ...
... Year Period, DUBLIN, Calif., April 28 SuperGen ... the first quarter ended,March 31, 2008., Total revenues ... $4.4 million for the same prior year period. Total ... in royalty revenue, compared,with $3.8 million for the same ...
... 28 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ), ... zinc finger DNA-binding proteins (ZFPs) for therapeutic gene,regulation ... G.,Wiggans to the company,s Board of Directors., ... Officer of,Connetics Corporation, a biotechnology company, from 1994, ...
Cached Biology Technology:Are nanobots on their way? 2Are nanobots on their way? 3SuperGen Reports 2008 First Quarter Financial Results 2SuperGen Reports 2008 First Quarter Financial Results 3SuperGen Reports 2008 First Quarter Financial Results 4SuperGen Reports 2008 First Quarter Financial Results 5SuperGen Reports 2008 First Quarter Financial Results 6SuperGen Reports 2008 First Quarter Financial Results 7SuperGen Reports 2008 First Quarter Financial Results 8SuperGen Reports 2008 First Quarter Financial Results 9Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... in a way that had never been observed in ... Current Biology, a Cell Press publication. The discoverywhich marks ... to perceive circular polarized light may lend mantis shrimp ... into a new dimension of vision, said Justin Marshall ...
... minerals--mineral nanoparticles--in oceans and rivers, atmosphere and soils, ... new ways of understanding Earth,s workings. Our planet,s ... driven by the properties of these minerals. ... universities in a paper published in this week,s ...
... finches are becoming more common as pets, but the ... includes some of the most exotic creatures on the ... multi-billion dollar enterprise, but expansion of the industry sometimes ... that afflict these unusual animals. The new Manual ...
Cached Biology News:Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3'Nanominerals' influence Earth systems from ocean to atmosphere to biosphere 2Veterinarians' guide to hedgehogs, chinchillas and chelonians.....oh, my! 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: